Genitourinary cancer (various)  
Genitourinary cancer (various)  
Urothelial cancer  
Urothelial carcinoma with DNA-repair defects  
Prostate cancer  
Castration-resistant prostate cancer  
Renal cell carcinoma  
Progressive renal cell carcinoma  

A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option

A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or Without VX-970 in Metastatic Urothelial Carcinoma

A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)

Phase 2 Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Study of AZD8156 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Dose escalation: solid tumors with PTEN or PIK3CB Mutations; dose expansion includes breast, prostate, and solid tumor cohorts)

A Phase II Randomized Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: October 20, 2019